High-dose methotrexate of no CNS benefit for patients with high-risk DLBCLMay 18, 2021B Cell LymphomaDLBCL
Evidence favors lower-dose R-CHOP for fit, very elderly DLBCL patientsApril 14, 2021B Cell LymphomaDLBCL
Don’t delay: Cancer patients need both doses of COVID vaccineMarch 15, 2021B Cell LymphomaMantle Cell LymphomaDLBCLCLLFollicular Lymphoma
Novel ddPCR assay precisely measures CAR T-cells after infusionFebruary 22, 2021DLBCLFollicular LymphomaB Cell Lymphoma
CAR T-cell products shine in real-world setting, reveal new insightsFebruary 18, 2021DLBCLB Cell Lymphoma
Chronic GVHD therapies offer hope for treating refractory diseaseFebruary 17, 2021DLBCLB Cell Lymphoma
Prognostic gene signature identifies high- vs. low-risk DLBCL patientsFebruary 17, 2021B Cell LymphomaDLBCL
Synthetic lethality: Triple combination is a viable strategy for B-cell malignanciesDecember 11, 2020B Cell LymphomaDLBCLCLL
